Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Life Sciences Mass Spectrometry, Department of Inorganic and Analytical Chemistry, University of Geneva, Geneva, Switzerland.
Nephrol Dial Transplant. 2022 Jun 23;37(7):1375-1383. doi: 10.1093/ndt/gfac012.
Post-transplantation diabetes mellitus (PTDM) is a major clinical problem in kidney transplant recipients (KTRs). Diuretic-induced hyperglycaemia and diabetes have been described in the general population. We aimed to investigate whether diuretics also increase PTDM risk in KTRs.
We included 486 stable outpatient KTRs (with a functioning graft ≥1 year) without diabetes from a prospective cohort study. Participants were classified as diuretic users and non-users based on their medication use verified by medical records.
At the baseline study, 168 (35%) KTRs used a diuretic (thiazide, n = 74; loop diuretic, n = 76; others, n = 18) and 318 KTRs did not use a diuretic. After 5.2 years [interquartile range (IQR) 4.0‒5.9] of follow up, 54 (11%) KTRs developed PTDM. In Cox regression analyses, diuretic use was associated with incident PTDM, independent of age, sex, fasting plasma glucose (FPG) and haemoglobin A1c (HbA1c) {hazard ratio [HR] 3.28 [95% confidence interval (CI) 1.84-5.83]; P <0.001}. Further adjustment for potential confounders, including lifestyle, family history of cardiovascular disease, use of other medication, kidney function, transplantation-specific parameters, BMI, lipids and blood pressure did not materially change the association. Moreover, in Cox regression analyses, both thiazide and loop diuretics associated with the development of PTDM, independent of age, sex, FPG and HbA1c [HR 2.70 (95% CI 1.24-5.29); P = 0.012 and HR 5.08 (95% CI 2.49-10.34); P <0.001), respectively].
This study demonstrates that diuretics overall are associated with an increased risk of developing PTDM in KTRs, independent of established risk factors for PTDM development. The association was present for both thiazide and loop diuretics.
移植后糖尿病(PTDM)是肾移植受者(KTR)的一个主要临床问题。利尿剂引起的高血糖和糖尿病在普通人群中已有描述。我们旨在研究利尿剂是否也会增加 KTR 中的 PTDM 风险。
我们纳入了来自一项前瞻性队列研究的 486 名稳定的门诊 KTR(移植后≥1 年移植物功能正常),无糖尿病。根据病历证实的用药情况,将参与者分为利尿剂使用者和非使用者。
在基线研究时,168 名(35%)KTR 使用利尿剂(噻嗪类,n=74;袢利尿剂,n=76;其他,n=18),318 名 KTR 未使用利尿剂。随访 5.2 年[四分位距(IQR)4.0-5.9]后,54 名(11%)KTR 发生 PTDM。在 Cox 回归分析中,利尿剂的使用与 PTDM 的发生相关,与年龄、性别、空腹血糖(FPG)和糖化血红蛋白(HbA1c)无关{风险比(HR)3.28[95%置信区间(CI)1.84-5.83];P<0.001}。进一步调整潜在混杂因素,包括生活方式、心血管疾病家族史、其他药物的使用、肾功能、移植特异性参数、BMI、脂质和血压,并没有改变这种关联。此外,在 Cox 回归分析中,噻嗪类和袢利尿剂均与 PTDM 的发生相关,与年龄、性别、FPG 和 HbA1c 无关[HR 2.70(95% CI 1.24-5.29);P=0.012 和 HR 5.08(95% CI 2.49-10.34);P<0.001])。
这项研究表明,利尿剂总体上与 KTR 发生 PTDM 的风险增加相关,与 PTDM 发生的既定危险因素无关。噻嗪类和袢利尿剂均存在这种关联。